You are here: Home » Companies » News
Business Standard

Abbott decides to withdraw 2 stent types from India

These are Alpine drug-eluting stent and Absorb dissolving stent

Press Trust of India  |  New Delhi 

Abbott decides to withdraw 2 stent types from India

Healthcare major has decided to withdraw two types of stents from the Indian market in the wake of drug price regulator National Pharmaceutical Pricing Authority's (NPPA's) move to cap the

The company has applied to the seeking to withdraw two kinds of stents.

These are drug-eluting and Absorb dissolving

An spokesperson said that following the NPPA's price ceiling decision, it "examined and re-examined" whether there is a sustainable way to make available two of the latest technologies in India.

The company took into consideration drug-eluting and the Absorb dissolving stents' higher manufacturing costs and other associated costs.

"We have determined it is not sustainable, and we have applied to the to withdraw these two stents," the spokesperson told PTI in an e-mailed statement.

The company said that presently, only a very small percentage of patients in India receive and Absorb stents.

"While we are aligned with the government's intent for broad access to care, we're disappointed that the concluded there is no differentiation in coronary technology," the company noted.

According to Abbott, it would continue to make available all other XIENCE coronary products within the ceiling price set by the

"and Absorb will continue to remain available while the government reviews our application. There is no shortage of stents," it added.

RECOMMENDED FOR YOU

Abbott decides to withdraw 2 stent types from India

These are Alpine drug-eluting stent and Absorb dissolving stent

These are Alpine drug-eluting stent and Absorb dissolving stent
Healthcare major has decided to withdraw two types of stents from the Indian market in the wake of drug price regulator National Pharmaceutical Pricing Authority's (NPPA's) move to cap the

The company has applied to the seeking to withdraw two kinds of stents.

These are drug-eluting and Absorb dissolving

An spokesperson said that following the NPPA's price ceiling decision, it "examined and re-examined" whether there is a sustainable way to make available two of the latest technologies in India.

The company took into consideration drug-eluting and the Absorb dissolving stents' higher manufacturing costs and other associated costs.

"We have determined it is not sustainable, and we have applied to the to withdraw these two stents," the spokesperson told PTI in an e-mailed statement.

The company said that presently, only a very small percentage of patients in India receive and Absorb stents.

"While we are aligned with the government's intent for broad access to care, we're disappointed that the concluded there is no differentiation in coronary technology," the company noted.

According to Abbott, it would continue to make available all other XIENCE coronary products within the ceiling price set by the

"and Absorb will continue to remain available while the government reviews our application. There is no shortage of stents," it added.
image
Business Standard
177 22

Abbott decides to withdraw 2 stent types from India

These are Alpine drug-eluting stent and Absorb dissolving stent

Healthcare major has decided to withdraw two types of stents from the Indian market in the wake of drug price regulator National Pharmaceutical Pricing Authority's (NPPA's) move to cap the

The company has applied to the seeking to withdraw two kinds of stents.

These are drug-eluting and Absorb dissolving

An spokesperson said that following the NPPA's price ceiling decision, it "examined and re-examined" whether there is a sustainable way to make available two of the latest technologies in India.

The company took into consideration drug-eluting and the Absorb dissolving stents' higher manufacturing costs and other associated costs.

"We have determined it is not sustainable, and we have applied to the to withdraw these two stents," the spokesperson told PTI in an e-mailed statement.

The company said that presently, only a very small percentage of patients in India receive and Absorb stents.

"While we are aligned with the government's intent for broad access to care, we're disappointed that the concluded there is no differentiation in coronary technology," the company noted.

According to Abbott, it would continue to make available all other XIENCE coronary products within the ceiling price set by the

"and Absorb will continue to remain available while the government reviews our application. There is no shortage of stents," it added.

image
Business Standard
177 22